GOLDEN, CO / ACCESSWIRE / December 9, 2021 / Panacea Life Sciences, Inc. (OTCQB:PLSH), (the "Company"), a cGMP certified, vertically integrated premium CBD and cannabinoid company, announces new partnership with MyPharma2Go to enter the growing Brazilian cannabis market. The partnership reinforces MyPharma2Go's already robust portfolio, allowing them to ensure a premium service in delivering the best global cannabis products to customers in Brazil.
Founded in 2017, MyPharma2Go works with market-leading brands recommended by top professionals across seven different cross-border e-commerce platforms to provide patients access to globally available medicines, supplements, and medical cannabis.
According to André Di Donato, CEO and founder of MyPharma2Go, in the last five years, MyPharma2Go has impacted more than 30,000 health professionals and has served more than 240,000 patients throughout Brazil. He also noted, "With this partnership with Panacea Life Sciences, we will continue with our purpose of ensuring a premium service in delivering the best global products to our customers in Brazil."
Since their founding in 2017, Panacea Life Sciences has upheld the highest standards for all their products across multiple categories, from oil drops and softgels to gummies and topicals. With a focus on Cultivating Everyday Wellness™ by making products that use only the highest quality cannabinoids, the brand continues to build trust and reliability with each new product in its lineup.
"Panacea is extremely honored to be accepted into MyPharma2Go's portfolio of quality products for the people of Brazil" commented Nick Cavarra, Executive Vice President of Sales & Marketing. "As the largest country in South America with a population of over 200 million people, our partnership with MyPharma2Go provides us an incredible pathway to reach Latin American consumers with Panacea's array of topical and ingestible products for humans and pets, and in turn, will increase revenues and shareholder value in 2022."
From the beginning, MyPharma2Go's goal has always been to make it easier for Brazilians to buy US-made dietary supplements and OTC products by building an e-commerce empire for healthcare. They have recently launched a direct-to-consumer portal that provides detailed information about the products, support services for their acquisition, and a personalized customer experience, with the seal of delivery guarantee throughout the national territory.
About Panacea Life Sciences Holdings, Inc.
Panacea Life Sciences, Inc. is a leader in production of legal, trace THC, hemp-derived cannabinoid products for consumers and pets that operates a 51,000 square foot cGMP certified facility in Golden, Colorado and the PANA Botanicals farm in western Colorado, complete with fully integrated extraction, manufacturing, testing and fulfillment. Panacea produces softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals for purchase online (www.panacealife.com) and in stores as well as in smart kiosk vending machines being rolled out nationally.
Panacea, which was founded by Leslie Buttorff in 2017 as a woman-owned business, has attracted $20 million in initial investments. In 2019, these were followed up with a $14 million investment from 22nd Century Group, Inc. (NASDAQ: XXII), a leading plant biotechnology company focused on technology to decrease nicotine in tobacco plants and uses its expertise for genetic engineering of hemp plants to modify cannabinoid levels used in manufacturing CBD, CBG and CBN.
If you would like more information about this topic or to learn more about Panacea and its products or our land-to-brand practices, please visit panacealife.com.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our contract in Brazil, including the perceived merits and anticipated outcome of consumer demand for and suitability of our products in retail locations and in general, and the expected growth of the CBD/hemp industry in which we operate. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. Other risks are included in filings with the SEC made by Panacea Life Sciences Holdings, Inc., parent company of Panacea. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.
Contact:
Nick Cavarra
SOURCE: Panacea Life Sciences, Inc